Literature DB >> 8186428

Concentration and sequence dependent synergism of ethyldeshydroxy-sparsomycin in combination with antitumor agents.

H P Hofs1, D J Wagener, V de Valk-Bakker, H van Rennes, H C Ottenheijm, W J de Grip.   

Abstract

The modulating effect of ethyldeshydroxy-sparsomycin (EDSM), an inhibitor of ribosomal protein synthesis, on cytostatic agents was studied on cultured B16 melanoma cells using the microculture tetrazolium test (MTT). The data were analyzed for true synergism using the combination index and the median effect principle. The extent of cytotoxic drug interaction was influenced by the duration of drug exposure, the dose ratio, as well as the treatment schedule. When drug ratios were used, synergism was observed upon pre- and post-treatment in combination with cisplatin, cytosine arabinoside (Ara-C), methotrexate (MTX) and 5-fluorouracil (5-FU). The combination of a fixed dose of EDSM was synergistic with cisplatin, Ara-C, vincristine (VCR) and MTX, in the order MTX > Ara-C > VCR > cisplatin, while the combinations with doxorubicin, 5-FU and etoposide (VP-16) were shown to be antagonistic. These results suggest that only certain drugs and treatment schedules might be worthwhile for combination studies with EDSM in vivo and indicate a role for EDSM as modifier of antitumor responses in cancer chemotherapy.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 8186428     DOI: 10.1097/00001813-199402000-00006

Source DB:  PubMed          Journal:  Anticancer Drugs        ISSN: 0959-4973            Impact factor:   2.248


  3 in total

1.  Interaction between cisplatin, 5-fluorouracil and vincristine on human hepatoma cell line (7721).

Authors:  Wei-Xue Tang; Ping-Yan Cheng; Yun-Peng Luo; Rui-Xue Wang
Journal:  World J Gastroenterol       Date:  1998-10       Impact factor: 5.742

2.  Characterization of sparsomycin resistance in Streptomyces sparsogenes.

Authors:  E Lázaro; E Sanz; M Remacha; J P G Ballesta
Journal:  Antimicrob Agents Chemother       Date:  2002-09       Impact factor: 5.191

3.  Altering chemosensitivity by modulating translation elongation.

Authors:  Francis Robert; Marilyn Carrier; Svea Rawe; Samuel Chen; Scott Lowe; Jerry Pelletier
Journal:  PLoS One       Date:  2009-05-01       Impact factor: 3.240

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.